Glycomine

Glycomine

Biotechnology, 953 St, San Carlos, California, Indiana, 94107, United States, 1-10 Employees

glycomine.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 65********

Who is GLYCOMINE

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replace...

Read More

map
  • 953 Indiana St, San Carlos, California, 94107, United States Headquarters: 953 Indiana St, San Carlos, California, 94107, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $10 Million to $25 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from GLYCOMINE

Glycomine Org Chart and Mapping

Employees

Helen Shapiro

Director of Clinical Operations

Naoko Matsui

Research and Development Scientist

Tristen Moors

Vice President, Clinical Operations and Patient Advocacy

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Glycomine

Answer: Glycomine's headquarters are located at 953 St, San Carlos, California, Indiana, 94107, United States

Answer: Glycomine's phone number is 65********

Answer: Glycomine's official website is https://glycomine.com

Answer: Glycomine's revenue is $10 Million to $25 Million

Answer: Glycomine's SIC: 2834

Answer: Glycomine has 1-10 employees

Answer: Glycomine is in Biotechnology

Answer: Glycomine contact info: Phone number: 65******** Website: https://glycomine.com

Answer: Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies substrates, enzymes, or proteins and to target those molecules to clinically relevant cellular compartments. Glycomines lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access